Sign in Subscribe

Latest

Clinical Breakthrough at ASH 2025: CLN-049 Demonstrates 50% Response Rate in TP53-Mutated AML via Novel FLT3xCD3 Engagement

Oncology

Clinical Breakthrough at ASH 2025: CLN-049 Demonstrates 50% Response Rate in TP53-Mutated AML via Novel FLT3xCD3 Engagement

Phase 1 data confirms extracellular FLT3 binding efficacy regardless of mutational status, offering a potential breakthrough for refractory subsets. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * Clinical Perspective Data presented today at

By Jitesh Rana, MD
TRPM8 Validation: Elismetrep Shows Promise in Phase 2b for Acute Migraine Without Thermoregulation Liability

Neurology

TRPM8 Validation: Elismetrep Shows Promise in Phase 2b for Acute Migraine Without Thermoregulation Liability

Kallyope's first-in-class oral antagonist meets co-primary endpoints, offering a distinct non-CGRP mechanism for refractory patients. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * Clinical Impact Analysis The landscape of acute migraine

By Jitesh Rana, MD
Altimmune’s Pemvidutide Achieves 59.1% MASH Resolution: A Potent "Defatting" Engine Faces the Fibrosis Lag Challenge

Metabolic

Altimmune’s Pemvidutide Achieves 59.1% MASH Resolution: A Potent "Defatting" Engine Faces the Fibrosis Lag Challenge

Phase 2b IMPACT trial data confirms best-in-class liver fat reduction, but a missed 24-week fibrosis endpoint necessitates a strategic pivot for Phase 3 design. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * What

By Jitesh Rana, MD
See all